Changing the first Overactive Bladder (OAB) therapy with Tolterodine ER to Fesoterodine in daily practice: The effect of aging on patient-reported treatment benefit in the IMPACTA study

Castro-Díaz D1, Miranda P2, Sánchez-Ballester F3, Lizarraga I4, Arumi D5, Rejas J6

Abstract Category

Detrusor Overactivity

Abstract 356
Non Discussion Poster
Scientific Non Discussion Poster Session 31
1. Department of Urology, Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain, 2. Department of Gynecology, Hospital de Fuenlabrada, Madrid, Spain, 3. Department of Urology, Hospital General Universitario, Valencia, Spain, 4. Medical Department, Pfizer SLU, 5. Medical Department, Pfizer Inc., 6. HEOR Department, Pfizer SLU